A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer

European Journal of Cancer

Volumn 47, Issue 9, 2011, Pages 1343-1354

  Adelstein, Barbara Ann ^a   Dobbins, Timothy A ^a   Harris, Carole A ^a   Marschner, Ian C ^b   Ward, Robyn L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

Author keywords

Cetuximab; Colorectal cancer; KRAS; Panitumumab; Systematic review

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; HUMAN; META ANALYSIS; METASTASIS; MONOTHERAPY; ONCOGENE K RAS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; GENES, RAS; HUMANS; MUTATION; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK; TREATMENT OUTCOME;

EID: 79957576342     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.03.031     Document Type: Article

References (40)

1. L. Liu, Y. Cao, and A. Tan Cetuximab-based therapy versus noncetuximab therapy in advanced or metastatic colorectal cancer: a meta-analysis of seven randomized controlled trials Colorectal Dis 12 5 2010 399 406
2. F. Nie, J. Shen, and J.L. Tong Meta-analysis: the efficacy and safety of monoclonal antibody targeted to epidermal growth factor receptor in the treatment of patients with metastatic colorectal cancer J Dig Dis 10 4 2009 247 257
3. K.Y. Chung, J. Shia, and N.E. Kemeny Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 23 9 2005 1803 1810 (Pubitemid 46211358)
4. L.B. Saltz, N.J. Meropol, and P.J. Loehrer Sr. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 7 2004 1201 1208 (Pubitemid 41079832)
5. F. Di Fiore, F. Blanchard, and F. Charbonnier Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy Br J Cancer 96 8 2007 1166 1169 (Pubitemid 46625066)
6. A. Lievre, J.-B. Bachet, and D. Le Corre KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 8 2006 3992 3995
7. C.J. Allegra, J.M. Jessup, and M.R. Somerfield American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy J Clin Oncol 27 12 2009 2091 2096
8. T.S. Maughan, R. Adams, and C.G. Smith Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy in first-line advanced colorectal cancer: mature results of the MRC COIN trial J Clin Oncol 28 2010 15s (abstr 3502)
9. Tveit K, Guren T, Glimelius B, et al. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The Nordic VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group. Ann Oncol. 2010; 21(Supplement 8): (abstr LBA20) doi:10.1093/annonc/ mdq601.
10. J. Tol, M. Koopman, and A. Cats Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 6 2009 563 572
11. R. Peto Misleading subgroup analyses in GISSI Am J Cardiol 66 7 1990 771 772
12. ISIS-2 Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Lancet 2 8607 1988 349 360
13. Gruppo Italiano per lo Studio della Streptochinasi nell Infarcto Miocardico (GISSI) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI) Lancet 2 8478 1986 397 402
14. S.T. Brookes, E. Whitely, and M. Egger Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test J Clin Epidemiol 57 3 2004 229 236 (Pubitemid 38456874)
15. P.M. Rothwell Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation Lancet 365 9454 2005 176 186 (Pubitemid 40091809)
16. R. Wang, S.W. Lagakos, J.H. Ware, D.J. Hunter, and J.M. Drazen Statistics in medicine-reporting of subgroup analyses in clinical trials N Engl J Med 357 21 2007 2189 2194
17. R.G. Amado, M. Wolf, and M. Peeters Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 10 2008 1626 1634
18. C. Bokemeyer, I. Bondarenko, and A. Makhson Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 5 2009 663 671
19. C.S. Karapetis, S. Khambata-Ford, and D.J. Jonker K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 17 2008 1757 1765
20. E. Van Cutsem, C.-H. Kohne, and E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 14 2009 1408 1417
21. J.F. Tierney, L.A. Stewart, D. Ghersi, S. Burdett, and M.R. Sydes Practical methods for incorporating summary time-to-event data into meta-analysis Trials 8 1 2007 16
22. T.J. Santner, and M.K. Snell Small-sample confidence intervals for p1-p2 and p1/p2 in contingency tables J Am Stat Assoc 75 1980 386 394
23. J.P.T. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 7414 2003 557 560 (Pubitemid 37088507)
24. L. Tian, T. Cai, and M.A. Pfeffer Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 × 2 tables with all available data but without artificial continuity correction Biostatistics 10 2 2009 275 281
25. P. Armitage, G. Berry, and J.N.S. Matthews Statistical methods in medical research 4th ed. 2002 Blackwell Science Oxford
26. S.G. Thomson Why and how sources of heterogeneity should be investigated? M. Egger, G. Davey Smith, D.G. Altman, Systematic Reviews in Health Care: Meta-Analysis in Context 2001 BMJ Publishing Group London, UK 157 175
27. J.Y. Douillard, S. Siena, and J. Cassidy Randomized, phase III trial of Panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 31 2010 4697 4705
28. J.R. Hecht, E. Mitchell, and T. Chidiac A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol 27 5 2009 672 680
29. M. Peeters, T.J. Price, and A. Cervantes Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J Clin Oncol 28 31 2010 4706 4713
30. D.J. Jonker, C.J. O'Callaghan, and C.S. Karapetis Cetuximab for the treatment of colorectal cancer N Engl J Med 357 20 2007 2040 2048 (Pubitemid 350106711)
31. E. Van Cutsem, M. Peeters, and S. Siena Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 13 2007 1658 1664 (Pubitemid 46797944)
32. Van Cutsem E, Lang I, Folprecht G, et al. Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: The influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trial. Amercian Society of Clinical Oncology (ASCO): Gastrointestinal Cancers Symposium; 2010. p. Abstract 281.
33. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Overall survival of patients with KRAS wild-type tumors treated with FOLFOX4 cetuximab as 1st line treatment for metastatic colorectal cancer: The OPUS study. ECCO 15-ESMO 34, 2009. p. Abstract No 6.079.
34. E.M. Ibrahim, J.M. Zekri, and B.M. Bin Sadiq Cetuximab-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of K-ras mutations Int J Colorectal Dis 25 6 2010 713 721
35. A. Grothey EGFR antibodies in colorectal cancer: where do they belong? J Clin Oncol 28 31 2010 4668 4670
36. K.R. Johnson, C. Ringland, and B.J. Stokes Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis Lancet Oncol 7 9 2006 741 746 (Pubitemid 44283658)
37. E.D. Saad, A. Katz, P.M. Hoff, and M. Buyse Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature Ann Oncol 21 1 2010 7 12
38. H.J. Andreyev, A.R. Norman, D. Cunningham, J.R. Oates, and P.A. Clarke Kirsten ras mutations in patients with colorectal cancer: the multicenter 'RASCAL' study J Natl Cancer Inst 90 9 1998 675 684 (Pubitemid 28222141)
39. S.D. Richman, M.T. Seymour, and P. Chambers KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial J Clin Oncol 27 35 2009 5931 5937
40. W. De Roock, D.J. Jonker, and F. Di Nicolantonio Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab Jama 304 16 2010 1812 1820